A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-lb in the treatment of patients with secondary progressive or progressive relapsing multiple sclerosis
- 28 February 2003
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 25 (2), 611-634
- https://doi.org/10.1016/s0149-2918(03)80100-5
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trialThe Lancet, 2002
- Relapses and Progression of Disability in Multiple SclerosisNew England Journal of Medicine, 2000
- Multiple SclerosisNew England Journal of Medicine, 2000
- Long Term Treatment of Multiple Sclerosis with Interferon-?? May Be Cost EffectivePharmacoEconomics, 2000
- The social impact of multiple sclerosis - a study of 305 patients and their relativesDisability and Rehabilitation, 2000
- Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosisBMJ, 1999
- Placebo-controlled multicentre randomised trial of interferon β-1b in treatment of secondary progressive multiple sclerosisThe Lancet, 1998
- A comprehensive assessment of the cost of multiple sclerosis in the United StatesMultiple Sclerosis Journal, 1998
- Revised estimate of the prevalence of multiple sclerosis in the united statesAnnals of Neurology, 1992
- THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDYBrain, 1989